Bone epithelioid hemangioma is a rare, benign vascular tumor that forms in bone. People with bone epithelioid hemangioma may notice localized pain or swelling, and doctors often find a lytic lesion on imaging. It can occur at any age but is more often recognized in young to middle-aged adults, and it tends to grow slowly. Mortality is very low, but lesions can recur if not fully treated. Treatment usually involves curettage or surgical excision, sometimes with bone grafting, and follow-up imaging is common.
Overview
Bone epithelioid hemangiomaSymptoms
Bone epithelioid hemangioma often causes a deep bone pain that worsens with activity or at night. You may notice swelling, tenderness, or limited movement near the spot; occasionally a fracture occurs. Early symptoms of Bone epithelioid hemangioma may be minimal.
Outlook and prognosis
Most people with bone epithelioid hemangioma do well with treatment, especially when the tumor is fully removed. It tends to grow slowly, and spread is uncommon, but local regrowth can happen and needs follow-up. Regular imaging helps catch changes early.
Causes and risk factors
Bone epithelioid hemangioma usually arises sporadically; the exact cause is unknown. Research suggests acquired (non-inherited) gene changes in vascular cells. No well-established environmental or lifestyle risk factors have been identified.
Genetic influences
Genetics play a limited, evolving role in bone epithelioid hemangioma. Most cases seem sporadic, though somatic gene fusions (such as FOS or FOSB) are found in many tumors. These changes arise in the tumor cells and are not typically inherited.
Diagnosis
Doctors suspect bone epithelioid hemangioma based on pain or swelling plus imaging (X‑ray, CT, MRI) showing a vascular bone lesion. The diagnosis of bone epithelioid hemangioma is confirmed by biopsy with pathology, often using immunostains to exclude look‑alike cancers.
Treatment and drugs
Treatment for bone epithelioid hemangioma focuses on removing or controlling the tumor while preserving function. Options often include curettage with bone grafting, limited surgical excision, and, when needed, embolization or targeted therapy for harder‑to‑reach areas. Follow‑up imaging helps catch regrowth early.
Symptoms
Bone epithelioid hemangioma can show up as a deep, nagging ache in one spot, swelling, or tenderness that makes everyday movement uncomfortable. For many, the first clue is pain with activity or at night, sometimes followed by a small, firm lump over the bone. These can be early symptoms of bone epithelioid hemangioma, especially when the area stays sore for weeks. Symptoms vary from person to person and can change over time.
A steady, localized ache develops in one bone and may worsen with standing, walking, or lifting. The spot often feels deep and hard to ignore. For many people with bone epithelioid hemangioma, pain is the main reason they seek care.
A small, firm bump can appear over the involved bone, sometimes with mild puffiness around it. Shoes or sleeves may start to rub against it. This can happen when the lesion sits near the surface of the bone.
The area may be sore when pressed, making tasks like leaning on a desk or carrying a bag uncomfortable. Tenderness often lines up with the precise spot of the lesion.
Pain can flare at night or after routine activity, like a long walk or climbing stairs. Rest may help, but the ache often returns.
How people usually first notice Bone epithelioid hemangioma?
Many people first notice bone epithelioid hemangioma when a dull, nagging ache in a limb or near a joint doesn’t go away, sometimes with mild swelling or tenderness over one spot and, less often, a small lump you can feel. Doctors are often alerted by an X-ray or MRI done for persistent pain or after a minor injury, which shows a well-defined bone lesion; this is usually followed by a biopsy to confirm the diagnosis. In children and adults alike, the first signs of bone epithelioid hemangioma can also include occasional warmth over the area or, rarely, a pathologic fracture when the bone is weakened.
Types of Bone epithelioid hemangioma
Bone epithelioid hemangioma is a rare, usually benign vascular tumor that starts in bone and can look and feel different from case to case. Symptoms don’t always look the same for everyone. Doctors recognize a few clinical patterns based on how many bones are involved and how the lesions behave, which helps explain differences in pain, swelling, or risk of local recurrence. When people search for types of bone epithelioid hemangioma, they’re usually asking how solitary versus multifocal disease compares.
Solitary lesion
A single tumor in one bone causes focused pain and a tender spot, often after activity. Swelling or a small lump over the area may be noticed, and imaging shows one main lesion. Local treatment usually works well, though follow-up checks are still important.
Multifocal disease
Lesions appear in several bones at once, so pain may show up in more than one location. People may have alternating aches—for example, in a rib one week and the foot the next. Care plans often include broader imaging and staged treatments.
Aggressive local behavior
Some lesions grow faster, erode nearby bone, or come back after surgery. Pain can be more persistent and there may be a higher risk of a small fracture in the affected bone. Treatment may involve wider removal and closer monitoring.
Soft-tissue extension
The bone lesion grows into nearby soft tissues, which can add a visible or palpable mass. This can make soreness and swelling more noticeable. Imaging helps map the full extent so surgeons can plan a clear margin.
Vertebral involvement
When the spine is affected, back pain and stiffness are common, and nerve-related symptoms can occur if the growth narrows nearby spaces. Bracing or activity changes may help while planning treatment. Share with your healthcare provider whether symptoms change with movement or rest.
What genetics can tell you about symptoms
Some people with bone epithelioid hemangioma have mutations in genes like FOS or FOSB, which can act like stuck-on growth switches in certain tumor cells. These changes are linked to pain, swelling, and sometimes a fragile spot or lytic lesion in the affected bone.
Causes and risk factors
The exact cause is unclear, and no lifestyle habit has been shown to trigger it. In bone epithelioid hemangioma, many tumors have changes in FOS or FOSB genes in the tumor cells. These gene changes arise in the growth itself and are not passed down in families. Doctors distinguish between risk factors you can change and those you can’t. There are no proven lifestyle or environmental risk factors, and risk factors for bone epithelioid hemangioma mainly reflect age, with cases most often in young to middle-aged adults.
Environmental and biological risk factors
Bone epithelioid hemangioma is a rare vascular tumor of bone. Clear environmental risk factors for bone epithelioid hemangioma have not been identified, and most cases appear sporadic. Researchers are still exploring how outside influences interact with our inner biology. Below are biological patterns and environmental contexts that may relate to risk, based on what’s known today.
Many diagnoses occur in young to middle adulthood. It can appear at any age, including teens and older adults.
Slightly more males are reported in some series. Females are also affected, and the difference is small.
The long bones of the legs and certain spine or head-and-neck bones are more often involved. This suggests some bones may be biologically more susceptible. Site of origin influences where symptoms start, not overall behavior.
A few reports describe lesions arising where there was earlier minor trauma or surgery. This link is uncertain, and most people with similar injuries never develop bone epithelioid hemangioma. Two people with the same exposure can react very differently—biology shapes the response.
Genetic risk factors
Bone epithelioid hemangioma often begins when certain genes in the cells lining blood vessels fuse or switch on in unusual ways. These are somatic changes—alterations found only in the tumor, not in the genes you were born with—so family members usually are not at increased risk. Risk is not destiny—it varies widely between individuals. Here’s what is known about genetic risk factors for bone epithelioid hemangioma.
FOSB gene fusions: Many tumors show changes that join FOSB to another gene, creating a fusion that drives growth. Examples include ZFP36–FOSB or WWTR1–FOSB. These fusions act like a stuck-on switch in the vessel-lining cells within bone.
FOS rearrangements: Some cases have rearrangements involving the related FOS gene. These changes activate similar cell programs and can produce the same look under the microscope. They are less common than FOSB fusions.
Somatic, not inherited: The genetic changes in bone epithelioid hemangioma are somatic, meaning they arise only in the tumor cells. They are not typically present in blood or saliva DNA and are not passed down in families. Family members usually do not need genetic testing for this tumor.
No known predisposition: At this time, no consistent inherited syndrome has been linked to a higher risk of bone epithelioid hemangioma. Most people have no family history of similar vascular tumors.
Testing can confirm: Doctors may use molecular tests to look for FOSB or FOS changes when the diagnosis is uncertain. Finding one of these fusions can help confirm bone epithelioid hemangioma and distinguish it from look-alike tumors.
Distinct genetics: Genes typical of other vascular tumors, such as WWTR1–CAMTA1 or YAP1–TFE3, are generally not found in bone epithelioid hemangioma. This helps pathologists separate it from related conditions that need different care.
Lifestyle risk factors
Bone epithelioid hemangioma is not caused by lifestyle, but daily habits can influence symptoms, complication risks, and recovery after treatment. Below are practical lifestyle risk factors for bone epithelioid hemangioma and how they may matter in day-to-day management. Understanding the lifestyle risk factors for bone epithelioid hemangioma can help you work with your care team to reduce pain and protect bone function.
Smoking reduces bone blood flow and impairs healing, which can worsen pain around a vascular bone tumor. It may also raise surgical complication rates and slow recovery if procedures are needed.
High alcohol intake weakens bone quality and balance, increasing the risk of falls and pathologic fracture at the lesion site. It can also interfere with post-procedure healing and pain control.
Running, jumping, or contact sports can increase mechanical stress at the tumor-bearing bone and provoke pain. In bones already weakened by the lesion, high-impact loads may raise fracture risk.
Low activity contributes to loss of bone and muscle support, which can worsen discomfort and limit function near the affected bone. Gentle, guided activity can help maintain stability without overloading the lesion.
Risk prevention
Bone epithelioid hemangioma is rare, and there’s no proven way to fully prevent it from developing. Prevention focuses on spotting changes early, protecting the affected bone, and lowering the chance of complications or recurrence after treatment. Prevention works best when combined with regular check-ups. Small, steady steps can support recovery and keep you safer while you and your care team monitor for any return.
New, ongoing bone pain, swelling, or a tender lump should be checked promptly to catch problems early. This can help identify early symptoms of bone epithelioid hemangioma and prevent fractures. Early imaging and, if needed, biopsy can guide safe treatment.
Ask for pathology review by an experienced bone tumor team to confirm the exact type. A correct diagnosis steers treatment that’s effective without being excessive. This lowers the risk of avoidable procedures and complications.
After surgery or curettage, regular check-ups and imaging can spot recurrence of bone epithelioid hemangioma early. Your doctor will set the schedule based on the bone involved and your healing. Reporting new pain between visits helps catch change sooner.
Until the bone is solid, follow weight-bearing limits and use braces or crutches if advised. Avoid high-impact or contact sports to lower fracture risk. Gradually return to activity as your team clears you.
Transmission
Bone epithelioid hemangioma is not contagious and cannot be passed from person to person through touch, the air, or shared items. People often wonder, “is Bone epithelioid hemangioma contagious?”—it isn’t; it’s a noncancerous growth of blood-vessel–forming cells in bone, not an infection. It is also not known to run in families; most cases happen by chance because of changes in the genetic material of the affected cells that occur after birth. Having bone epithelioid hemangioma does not put family members or close contacts at risk.
When to test your genes
Bone epithelioid hemangioma is not usually linked to inherited mutations, so routine genetic testing isn’t standard. Consider tumor genetic testing if the diagnosis is uncertain, the lesion behaves aggressively or recurs, or to guide targeted therapy in clinical trials. Seek germline testing only if there’s a strong family history of vascular tumors or related syndromes.
Diagnosis
Bone pain that lingers, a tender bump near a joint, or an unexpected finding on an X-ray after a minor injury can be the first clues that lead to evaluation. Doctors usually begin with your story and simple imaging, then move to targeted tests to confirm what’s going on. Because the condition is rare and can resemble other bone tumors, how bone epithelioid hemangioma is diagnosed typically involves both scans and a biopsy. Many people feel relief just knowing what’s really going on.
Your clinician asks about pain patterns, swelling, and any recent injuries. They also check the sore area for tenderness and changes in movement.
Standard bone X-rays can show a small hole or lesion in the bone with certain features that suggest a vascular tumor. X-rays help decide which further tests you need.
MRI maps the lesion’s size and whether it extends into nearby soft tissue. This helps surgeons plan and protects nearby nerves and joints.
CT shows fine detail of the bone wall and any subtle thinning or small breaks. It is useful when X-ray findings are unclear or surgery is being considered.
Stages of Bone epithelioid hemangioma
Bone epithelioid hemangioma does not have defined progression stages. It tends to behave as a localized, slow-growing vascular tumor in bone, so doctors focus on the number and location of lesions rather than a stepwise stage model. Different tests may be suggested to help confirm the diagnosis and rule out look-alike conditions. Early symptoms of bone epithelioid hemangioma can include a dull, activity-related ache or swelling, and evaluation usually involves X-rays and MRI, followed by a biopsy for a clear answer; monitoring often relies on symptoms and periodic imaging to track growth or new spots.
Outlook and prognosis
Looking ahead can feel daunting, but most people with bone epithelioid hemangioma do well over the long term. This rare vascular tumor tends to grow slowly and often stays confined to one area of bone, so life expectancy is usually normal. When it causes problems, it’s most often pain with activity, a tender spot over the bone, or a fracture if the lesion weakens the bone. Early care can make a real difference, especially if you’re noticing early symptoms of bone epithelioid hemangioma like persistent, localized bone pain or swelling that doesn’t ease with rest.
Doctors call this the prognosis—a medical word for likely outcomes. In general, treatment such as curettage (scooping out the tumor), targeted removal, and sometimes stabilizing the bone leads to good control. Recurrence can happen, especially if tiny tumor areas are left behind, but repeat treatment usually works. Spread to other sites is uncommon, and transformation into a more aggressive cancer is very rare.
Everyone’s journey looks a little different. People with larger or multiple lesions, or those in weight‑bearing bones, may need closer monitoring and, at times, additional procedures to prevent fractures. Most people return to regular routines after recovery, with periodic imaging to watch for regrowth. Talk with your doctor about what your personal outlook might look like, including how often to follow up and what to watch for between visits.
Long-term effects
Bone epithelioid hemangioma tends to behave in a slow-growing, locally recurrent way, with most long-term effects tied to the bone and nearby joints. Long-term effects vary widely, and many people do well after treatment. Many first notice deep, nagging pain or swelling—early symptoms of bone epithelioid hemangioma—but over time the focus is usually on protecting bone strength and function. Serious spread to distant sites is uncommon.
The tumor can return in the same area months or years later. When it comes back, it usually grows slowly and stays localized.
Ongoing changes can thin the bone and raise the risk of fracture. Breaks may happen after a minor fall or routine twist.
Aching, tenderness, or pressure at the site may persist. For many, symptoms flare with activity and ease with rest.
If the lesion is near a joint, movement can feel limited over time. This can make bending, lifting, or long walks harder.
How is it to live with Bone epithelioid hemangioma?
Living with bone epithelioid hemangioma often means navigating periods of uncertainty around pain, swelling, or tenderness at the affected site, along with scans and occasional procedures to confirm what’s changing and why. Many people manage well once a care plan is in place—treatments can range from watchful monitoring to surgery or targeted therapies—and day-to-day life typically returns to familiar routines between check-ins. Physical limits may crop up during flares or recovery, which can affect work, sports, or caregiving, so pacing activities and using pain-management strategies makes a real difference. For family and friends, offering flexible support—rides to appointments, help with chores, or simply steady reassurance—helps reduce stress and keeps life feeling steady.
Treatment and drugs
Bone epithelioid hemangioma is usually treated with surgery, since removing the tumor often eases pain and lowers the chance it will come back in the same spot. Surgeons may do a simple curettage (scooping out the lesion) sometimes with bone cement or graft, or a wider excision if the tumor is larger or in a fragile area; in weight‑bearing bones, internal fixation may be used to prevent fractures. If surgery isn’t possible or if disease involves multiple sites, doctors may consider medicines that slow blood vessel growth, such as interferon‑alpha or bevacizumab, or targeted options in select cases; radiation therapy can be used sparingly for unresectable or recurrent disease. Treatment plans often combine several approaches, and follow‑up imaging helps check healing and watch for recurrence. Your doctor can help weigh the pros and cons of each option.
Non-drug treatment
Bone epithelioid hemangioma is a slow-growing vascular tumor, and many non-drug options focus on stabilizing the bone, relieving symptoms, and preventing recurrence. Non-drug treatments often lay the foundation for care, with surgery or image-guided procedures used when needed. Plans are individualized based on the bone involved, symptoms, and whether the lesion is single or in multiple sites.
Careful monitoring with scheduled scans can be appropriate for small, stable, symptom-free lesions. If early symptoms of bone epithelioid hemangioma—like a mild, nagging ache or swelling—appear, the plan can be adjusted promptly.
The surgeon removes the lesion by scraping it from the bone, sometimes adding bone graft to fill the space. This approach often preserves nearby joints and function.
Removing the tumor with a small rim of healthy bone may be advised if it recurs or weakens the bone. This can lower the risk of the hemangioma coming back.
Graft from your own bone or a donor can strengthen areas left weak after removal. It supports healing and helps the bone regain shape and stability.
Your genes may have an impact on how drugs work for you
Genes can affect how your body absorbs, breaks down, and responds to medicines for bone epithelioid hemangioma, changing both benefit and side‑effect risk. Pharmacogenetic testing, when available, may guide dosing or drug choice to improve safety and effectiveness.
Pharmacological treatments
Medicines for bone epithelioid hemangioma are usually considered when surgery isn’t possible, when lesions are in several places, or to manage pain and swelling day to day. Options range from simple pain relievers to targeted drugs used off-label for difficult vascular bone tumors. Not everyone responds to the same medication in the same way. Your care team will tailor choices to the location, number of lesions, and how symptoms affect your routine, and may discuss medical treatment options for bone epithelioid hemangioma if you’re not a candidate for surgery.
Acetaminophen or NSAIDs (like ibuprofen or naproxen) can ease bone pain and reduce swelling. Short courses of prescription pain medicines may be used for flare-ups.
Drugs such as zoledronic acid or pamidronate may help reduce bone pain and slow activity in affected bone. They’re given by IV at intervals and require monitoring for kidney function and rare jaw problems.
A short course of oral prednisone or a targeted steroid injection (e.g., triamcinolone) can calm inflammation around a painful lesion. Repeated or long-term use is limited by side effects like blood sugar changes and bone thinning.
This targeted drug is used off-label for complex vascular tumors and may help shrink or stabilize difficult bone lesions. Regular blood tests and infection precautions are needed because it can suppress the immune system.
Genetic influences
For most people, genetics influence bone epithelioid hemangioma at the tumor level rather than through inherited risk. It’s natural to ask whether family history plays a role. Current research shows bone epithelioid hemangioma is almost always sporadic, caused by gene changes that arise only in the tumor cells, not in the rest of the body. Many tumors show a gene fusion—two genes abnormally joined together—most often involving FOS or FOSB, which can push the local blood vessel cells to grow more than they should. Because these changes are acquired and not present in your eggs or sperm, bone epithelioid hemangioma is not considered hereditary, and relatives are not at increased risk. Doctors may test a sample of the tumor for these fusions to confirm the diagnosis and to tell it apart from look-alike conditions, but this testing does not usually change family screening.
Is Bone epithelioid hemangioma genetic?
Genetics play a limited, evolving role in bone epithelioid hemangioma. Most cases seem sporadic, though somatic gene fusions (such as FOS or FOSB) are found in many tumors. These changes arise in the tumor cells and are not typically inherited.
Pharmacogenetics—how genetics influence drug effects
For most people, treatment is guided mainly by the tumor’s behavior and location, with surgery as the mainstay. Testing the tumor tissue for specific gene changes—often involving FOS or FOSB—can confirm the diagnosis and distinguish it from other vascular tumors, which can change the overall treatment plan. There are currently no approved medicines that directly target these gene changes, though results may help with clinical trial discussions.
Medication choices around care—pain control, antibiotics, blood thinners, or rare use of systemic therapies—can be influenced by how your body processes drugs. Not every difference in response is genetic, but variations in genes that affect drug‑metabolizing enzymes (for example, CYP2D6 for codeine and tramadol, or CYP2C9 and VKORC1 for warfarin) can guide dosing to improve safety and benefit. Your care team may use genetic results when available, together with blood tests and close follow‑up; research on the pharmacogenetics of Bone epithelioid hemangioma is still limited.
Interactions with other conditions
Day to day, bone pain or swelling from bone epithelioid hemangioma can be hard to separate from aches due to arthritis, overuse, or an old injury, and this can delay getting the right care. Doctors call it a “comorbidity” when two conditions occur together, and when bone epithelioid hemangioma shows up alongside osteoporosis or long‑term steroid use, the affected bone may be more likely to weaken or fracture. If you have a history of cancer, bone epithelioid hemangioma can look like spread to the bone on scans, so your team may order targeted imaging or a biopsy to tell them apart. Blood thinners and clotting problems don’t cause bone epithelioid hemangioma, but they can raise bleeding risk during biopsy or surgery, so plans are adjusted to keep you safe. Because early symptoms of bone epithelioid hemangioma often mimic infection or inflammation, sharing a full health and medication history helps your clinicians sort out what’s related and what’s not.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described small, painful bumps on bone that seemed to grow slowly and sometimes bled under the skin, long before scans could show what was happening inside. Family doctors and surgeons noted that these lesions often appeared in the long bones of the arms or legs, the spine, or the ribs, and that they tended to look vascular—full of tiny blood channels—when examined during surgery. Early case notes focused on day-to-day impact: nagging, localized pain, swelling that made clothing or movement uncomfortable, and occasional tenderness after minor bumps.
First described in the medical literature as a vascular tumor of bone with a distinctive “epithelioid” cell pattern, bone epithelioid hemangioma sat for years in a gray zone between clearly benign and clearly aggressive bone conditions. Pathologists recognized the puzzle pieces under the microscope—plump endothelial cells lining small vessels and a mix of inflammation—but different centers used different names. Some reports grouped it with hemangiomas, others with borderline tumors, and a few confused it with malignancies, which led to more extensive treatments than were sometimes needed.
As medical science evolved, imaging and biopsy techniques sharpened the picture. Plain X‑rays and later CT and MRI studies showed well-defined, sometimes lytic areas in bone with a rim that suggested a slow-growing process. Side-by-side with those images, improved pathology criteria separated bone epithelioid hemangioma from look‑alike entities, including low‑grade angiosarcoma and epithelioid hemangioendothelioma. This clearer boundary reduced overdiagnosis of cancer and guided surgeons toward limited excision or curettage when appropriate.
In recent decades, knowledge has built on a long tradition of observation. Larger case series, better follow‑up, and refined staining techniques confirmed that most bone epithelioid hemangiomas behave in a locally recurrent but overall indolent way: they can come back in the same spot if not fully removed, but they rarely spread. Reports also documented that lesions can occur as single sites or, less often, in multiple bones at once, which explained why some people experienced symptoms in more than one area over time.
Advances in genetics added another layer. Researchers identified recurrent gene fusions in some epithelioid vascular tumors of soft tissue and bone, helping anchor bone epithelioid hemangioma within the family of vascular lesions and distinguish it from more aggressive relatives. While genetic testing is not always required, these findings supported the modern classification used by bone tumor specialists and pathologists.
Looking back helps explain why recommendations today emphasize matching what is seen on imaging with what is found under the microscope. The historical shifts—from scattered case reports and mixed naming to agreed‑upon criteria—have improved accuracy, reduced unnecessary aggressive treatments, and set the stage for tailored care that focuses on symptom relief, function, and careful monitoring for local recurrence.